Short Interest in ImmuCell Co. (NASDAQ:ICCC) Decreases By 54.3%

ImmuCell Co. (NASDAQ:ICCC) saw a large decrease in short interest in the month of September. As of September 15th, there was short interest totalling 8,500 shares, a decrease of 54.3% from the August 31st total of 18,600 shares. Currently, 0.2% of the company’s shares are short sold. Based on an average trading volume of 35,800 shares, the days-to-cover ratio is presently 0.2 days.

Hedge Funds Weigh In On ImmuCell

A hedge fund recently bought a new stake in ImmuCell stock. Mesirow Financial Investment Management Inc. bought a new stake in shares of ImmuCell Co. (NASDAQ:ICCC) in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 12,178 shares of the biotechnology company’s stock, valued at approximately $65,000. Mesirow Financial Investment Management Inc. owned approximately 0.16% of ImmuCell as of its most recent SEC filing. 13.47% of the stock is currently owned by hedge funds and other institutional investors.

ImmuCell Trading Down 1.7 %

ICCC traded down $0.06 on Friday, hitting $3.55. 16,710 shares of the company were exchanged, compared to its average volume of 18,958. The company has a debt-to-equity ratio of 0.42, a quick ratio of 0.77 and a current ratio of 2.37. ImmuCell has a 12 month low of $3.34 and a 12 month high of $5.59. The firm has a fifty day simple moving average of $3.79 and a two-hundred day simple moving average of $4.43. The stock has a market capitalization of $27.73 million, a PE ratio of -6.96 and a beta of 0.56.

ImmuCell (NASDAQ:ICCC) last issued its earnings results on Tuesday, August 13th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter. ImmuCell had a negative return on equity of 16.35% and a negative net margin of 17.44%. The firm had revenue of $5.47 million during the quarter.

ImmuCell Company Profile

ImmuCell Corporation, an animal health company, develops, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company operates through two segments, Scours and Mastitis. It offers First Defense, an orally delivered scours preventive product for calves with claims against E.